Skip to main content
Top

Investigational New Drugs

Issue 5/2023

Content (14 Articles)

Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia

Carlos Eduardo de Castro Alves, Serge L. Bogza, Nathalie Bohdan, Alexander B. Rozhenko, Alice de Freitas Gomes, Regiane Costa de Oliveira, Renata Galvão de Azevedo, Larissa Raquel Silva Maciel, Anamika Dhyani, Andriy Grafov, Gemilson Soares Pontes

Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper

Lina Li, Fengquan Chen, Mengzhe Li, Yongxiang Liao, Yongjie Wang, Wen Jiang, Yun Luan, Xia Xue

Development and characterization of fused human arginase I for cancer therapy

  • Research

Snehal Sainath Jawalekar, Priyanka Sugriv Kawathe, Nisha Sharma, J Anakha, Kulbhushan Tikoo, Abhay H. Pande

Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation

Mingzhu Pan, Yali Liu, Tian Sang, Jiajun Xie, Huishu Lin, Jianpeng Wei, Shuai Shao, Yanying Zheng, Juan Zhang

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, Victor Moreno, Ana Oaknin, Daniel Castellano, Geoffrey I. Shappiro, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Daniel Rueda, Ali Zeaiter, Ahmad Awada, Ana Santaballa, Khalil Zaman, Jalid Sehouli, Vivek Subbiah

Cytotoxicity of poly-guanidine in medulloblastoma cell lines

Gabriel Gallo-Oller, Teresita Díaz de Ståhl, Ayodele Alaiya, Sten Nilsson, Anders R. Holmberg, Marcela Márquez-Méndez

Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models

Rachel C.T. Lam, Connie W.C. Hui, C. H. Wong, K. W. Lo, Anna C.M. Tsang, Edwin P. Hui, Anthony T.C. Chan, Brigette B.Y. Ma

Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab

Markus Haas, Alexander Lein, Thorsten Fuereder, Julia Schnoell, Faris F. Brkic, David T. Liu, Lorenz Kadletz-Wanke, Gregor Heiduschka, Bernhard J. Jank

A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia

Tatsuji Mino, Hiroshi Ureshino, Taichi Ueshima, Naoki Kashimoto, Tomonori Yamaguchi, Kazuhito Naka, Toshiya Inaba, Tatsuo Ichinohe

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma

Kenta Yamaoka, Kei Irie, Nobuhiro Hiramoto, Masaki Hirabatake, Hiroaki Ikesue, Tohru Hashida, Tadashi Shimizu, Takayuki Ishikawa, Nobuyuki Muroi

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more